TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Maxera Large Cups - Canada

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient received a Maxera Cup with an outer diameter of 64 mm or 66 mm.~* The Zimmer Maxera Cup is indicated for non-cemented use in skeletally mature individuals undergoing primary surgery for rehabilitating hips damaged as a result of non-inflammatory degenerative joint disease (NIDJD) including but not limited to osteoarthritis, avascular necrosis, post-traumatic arthritis, congenital hip dysplasia, and inflammatory joint disease (IJD), e.g. rheumatoid arthritis if bone quality is adequate.~Exclusion Criteria:~* Active, old, or remote infection of the hip.~* Osteoradionecrosis.~* Local bone tumors and/or cysts.~* Patients with poor bone quality, where there is inadequate bone to support the implant(s).~* Neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation.~* Allergy to the implanted material.~* Patient's physical conditions that would eliminate or tend to eliminate adequate implant support or prevent the use of an appropriately sized implant, e.g. previous surgery, insufficient quality or quantity of bone resulting from conditions such as cancer or congenital dislocation, metabolic bone disease of the upper femur or pelvis, femoral osteotomy revision, girdle stone revision, osteoporosis, osteomyelitis, neuromuscular compromise or vascular deficiency in the affected limb in sufficient degree to render the procedure unjustifiable (e.g. absence of musculoligamentous supporting structures, joint neuropathy) or other conditions that may lead to inadequate skeletal fixation~* Do not use ceramic femoral heads which are not BIOLOX delta or BIOLOX OPTION with Maxera components.~* Use of this device when a less invasive procedure would be sufficient.~* Skeletal immaturity.~* Any nerve or muscle disease that may have a negative effect on gait or weight bearing~* Loss of abductor musculature in the affected limb.~* Poor skin coverage around the hip joint.~* Rapid disease progression as obvious by joint destruction or bone absorption seen on x-ray.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: None

Study Arms:
- Patient who received a Maxera Cup of large diameter (Type: None): Patient received a Maxera Cup with an outer diameter of 64 mm or 66 mm between Nov 2011 and Feb 2018.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/Legally Acceptable Representative(s) (LAR(s)) can and will comply with the requirements of the protocol.~* Filipino male or female subjects whose age at the first vaccination with Synflorix™ in this PMS should not be less than 6 weeks of age.~* Filipino male or female subjects who enter the PMS at the second dose should not be less than 10 weeks of age.~* Filipino male or female subjects who enter the PMS at the third dose should not be less than 14 weeks of age.~* Filipino male or female subjects who enter the PMS at the booster dose (i.e. if they have received Synflorix™ in the previous dose/s outside the PMS) should not be less than 10 months of age. The time interval between the primary vaccination and booster dose should be at least 6 months. For the booster dose, subjects who received PCV-7/-13 or Synflorix™ in their primary vaccination series will be allowed to take part in the PMS.~* Written and signed informed consent obtained from the parents/LAR(s) of the child. Where parents/LAR(s) are illiterate, the consent form will be countersigned by a witness.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Acute disease and/or fever at the time of vaccine administration.~* Fever is defined as temperature ≥ 37.5°C (99.5°F) on axillary, infrared or tympanic setting.~* Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* History of chronic condition(s) requiring treatment such as cancer or autoimmune diseases.~* Hypersensitivity to latex (found in syringe-tip cap and plunger).~* Any contraindications as stated in the Prescribing Information.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Synflorix Group (Type: None): Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man and women, aged from 18 to 80 years.~* Social security affiliation~* Inclusion from day 3 to day 15 after stroke or brain haemorrhage~* Hemiparesia with upper limb motor deficit (Fugl-Meyer score - hand \< or = 10)~* Informed consent~Exclusion Criteria:~* Score NIHSS \> 20~* Depression (criteria DSM5-R) with MADRS score \> 19~* History of recurrent bipolar or depressive disorders.~* History of behavior or suicidal idea~* Family history of extension of the interval QT or congenital long interval QT~* History of clinical stroke~* Aphasia preventing correct evaluation of motor and depression scales.~* Patients treated by antidepressant drugs, monoamine oxidase inhibitor (IMAO), and neuroleptics in the past month~* Benzodiazepines within 48 hours preceding inclusion.~* Intolerance or allergy to fluoxetine (Sandoz® 20 mg pill)~* Severe swallowing disorders preventing oral administration of the treatment~* Planned carotid surgery~* Pregnant or breast-feeding woman~* Hepatic failure (TGO and TGP \>2N); severe renal failure (creatinine \>180micromol/l)~* Concomitant severe disease not allowing follow-up.~* Participation to another therapeutic study.~* Contraindication to MRI and TMS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ProChondrix® CR Articular Cartilage Restoration Evaluation (PACE) Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed by physician to have a cartilage defect in the knee, ankle, foot or hip that requires surgical intervention;~* Will be having, or has had, a cartilage repair procedure using ProChondrix CR;~* Has the ability to understand the requirements of the registry, to provide written informed consent and to comply with the registry protocol;~Exclusion Criteria:~• Is a ward of the state, prisoner, or transient.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Articular Cartilage Defect of the Knee (Type: None): Patients, who undergo an articular cartilage repair of the knee using ProChondrix CR.
- Articular Cartilage Defect of the Ankle (Type: None): Patients, who undergo an articular cartilage repair of the ankle using ProChondrix CR.
- Articular Cartilage Defect of the Foot (Type: None): Patients, who undergo an articular cartilage repair of the foot using ProChondrix CR.
- Articular Cartilage Defect of the Hip (Type: None): Patients, who undergo an articular cartilage repair of the hip using ProChondrix CR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written informed consent with HIPAA authorization~* Has cervical cancer and is a candidate for surgical intervention, with lymph node dissection being a part of the surgical plan.~* Is at least 18 years of age at the time of consent~* Has an ECOG performance status of Grade 0 to 2~* Has the following International Federation of Gynecology and Obstetrics (FIGO) IA2-IIA1staging. Subjects with a single enlarged/suspicious node on PET/CT will still be considered eligible as consistent with FIGO guidelines.~* If of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year~Exclusion Criteria:~* The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 30 days prior to Lymphoseek administration~* Has had previous surgery or radiation to node basins that would be involved in the ILM procedure~* Has a known allergy to dextran~* Is breast-feeding or pregnant~* Before the administration of Lymphoseek, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical~* Is scheduled for surgery and/or another invasive procedure other than the primary surgical intervention within the 3 days after Lymphoseek administration~* Has received an investigational product within the 30 days prior to Lymphoseek administration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tc99m tilmanocept (Type: EXPERIMENTAL): 2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of SCLC;~* Limited or extensive-stage disease in patients who have received a single chemotherapy regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed after completion of first-line chemotherapy (sensitive relapse);~* Age \>/= 18 years;~* ECOG Performance Status 0-2;~* Life expectancy of at least 12 weeks;~* Measurable lesions according to RECIST criteria;~* Adequate cardiac, hepatic, renal, and bone marrow function;~* Written informed consent.~Exclusion Criteria:~* Prior treatment with an HDAC inhibitor;~* Symptomatic and/or unstable pre-existing brain metastases;~* Superior Vena Cava Syndrome;~* Spinal cord compression;~* Severe or uncontrolled medical diseases (Hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of study, chronic renal disease, or active uncontrolled infections);~* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ;~* Pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat/Topotecan (Type: EXPERIMENTAL): Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.~Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected infection (no clear-cut source of infection) as defined by the treating physician~* Empiric antibiotic treatment~* No clear-cut source of infection by clinical or microbiological criteria~* ICU patient~* Informed consent~Exclusion Criteria:~* Age \<18 years~* Pregnancy~* Hemodynamic instability defined as persistent hypotension, need for on-going aggressive resuscitation and/or vasopressor support to maintain an adequate mean arterial blood pressure~* Need for antibiotic prophylaxis~* Patient withdrawn from empiric antibiotic treatment before Day 4~* Severely immuno-compromised patient (liver cirrhosis (Child-Pugh class C), immunosuppressive drugs after transplantation, neutropenia (absolute neutrophil count \<1000 counts/L), CD-4 count less than 200)~* Patient with suspected bacterial or fungal endocarditis~* Patient with suspected meningitis~* Cardiopulmonary bypass within the last 7 days1)~* Major surgery within the last 7 days (surgery that induces a major inflammatory response such as heart or aortic surgery or major abdominal surgery (i.e. duodenopancreatectomy) or any surgery requiring massive blood transfusion.)~* Multiple trauma within the last 7 days~* Cardiopulmonary resuscitation (CPR) within the last 7 days~* Burns \>20% body surface area~* Patient in terminal status referred for palliative care~* Patient with advanced directives or Do Not Resuscitate (DNR) orders~* Patient who is already enrolled in another therapeutic clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Standard treatment
- PCT (Type: EXPERIMENTAL): PCT guided arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Russian Registry of Patients With nAMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> to 18 years~* Male or female patients diagnosed with nAMD (with or without previous treatment for nAMD including but not limited to PDT, laser coagulation, vitamins, retinolamine, emoxipine, anti-VEGF therapy or any surgery for nAMD).~* Willing and able to provide informed written consent personally or by legal proxy~Exclusion Criteria:~* The patient does not meet the inclusion criteria;~* The patient is simultaneously participating in a different nAMD therapy study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nAMD patients (Type: None): patients diagnosed with Neovascular Age-Related Macular Degeneration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>18 years old~* Accept to participate in the study~* uterine leiomyomas who have \>2 risk factors for mesenchymal uterine malignant tumor OR sonographic suspicion of atypical leiomyoma.~Exclusion Criteria:~* \< 18 years~* Not being capable of understanding the study design

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: [124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients \>/= 18 years on the day of signing consent.~2. A diagnosis of diabetes mellitus, type I or II, as evidenced either by HbA1c\>6.5% or receipt of antidiabetic medication at time of enrollment.~3. Ability to provide informed consent~4. An inframalleolar ulcer of perfusion, extent/size, depth/tissue loss, infection and sensation (PEDIS) grade 2 or 3. At the discretion of the Investigator, patients with PEDIS grade 4 infections may be included if they are sufficiently stable.~5. For females of childbearing potential, a negative urine pregnancy test on the day of dosing.~6. For females of childbearing potential, a willingness to use 2 methods of contraception for 30 days after receiving \[124I\]FIAU.~7. Ability to return for all study assessments.~8. Clinically euthyroid, or on stable thyroid replacement therapy.~Exclusion Criteria:~1. Patients who ar unable to comply with study requirements.~2. Indication, in the opinion of the principal Investigator for urgent surgery that would preclude the time needed for PET-CT scanning, or clinical instability that precludes PET-CT scanning.~3. History of an inherited mitochondrial disorder (eg. Leber's hereditary neuropathy, neuropathy, ataxia, retinitis pigmentosa and ptosis \[NARP\], myoneurogenic gastrointestinal encephalopathy \[MNGIE\], myocolonic epilepsy with ragged red fibers \[MERFF\] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and stroke-like syndrome \[MELAS\])~4. Alanine aminotransferase (ALT)\>5x Upper Limit of Normal (ULN) OR aspartate aminotransferase (AST) \>5x ULN.~5. Body mass that exceeds the rating of the CT table.~6. Hypersensitivity to iodine.~7. Pregnant or breast-feeding.~8. Any condition that would put the patient at unreasonable risk in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [124I]FIAU (Type: EXPERIMENTAL): Single intravenous injection of \[124I\]FIAU in patients with diabetic foot infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with AML in second complete remission~* HLA-identical related (HLA \* A, B, and DR) or HLA-compatible unrelated donor with maximum of one Ag mismatch~* Ages 18-60 years~* Written informed consent from the patient~* Written informed consent from the donor~* No major organ dysfunction~Exclusion Criteria:~* Cardiac failure (New York Heart Association \[NYHA\] grade II-IV)~* Renal failure (creatinine \> 2.0 mg/dl)~* Hepatic failure (total bilirubin \> 3 mg/dl)~* Severe neurological/psychiatric disorder~* Previous allogeneic HSCT~* Contra-indications for used drugs~* HIV infection~* Non-compliance to processing of personal data according to the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- conditioning therapy with 12 Gy TBI / cyclophosphamide 120 (Type: ACTIVE_COMPARATOR): None
- conditioning therapy with 8 Gy TBI / fludarabine 120 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Insertion of Axillary Impella® With VA ECMO

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18~* Impaired LV systolic function with ≤35% of left ventricular ejection fraction (LVEF)~* Enlarged LV with ≥50mm of left ventricular diastolic diameter (LVEDD) on echocardiogram~Exclusion Criteria:~* Non-cardiac etiology~* Surgically correctable cardiac abnormality~* Recent significant pulmonary embolism~* Severe pulmonary hypertension~* Acute aortic dissection~* Presence of mechanical aortic valve prosthesis~* Presence of left ventricle thrombus~* Pre-existing Impella® 5.0~* Critical aortic stenosis~* Uncorrectable system malperfusion under ECMO support~* Significant cerebrovascular accident

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early axillary Impella® (Type: EXPERIMENTAL): Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues